Organization
Oncology Therapeutic Development
21 abstracts
2 posters
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
Web-based patient-reported outcome measures (PROMs) in elderly cancer patients: A French multicentric prospective feasibility trial (the FASTOCH study).Org: Ana Health, Centre Hospitalier Louis Pasteur, Dedalus, Centre Saint Jean, Vendôme Hospital,
Abstract
Artificial intelligence (AI) –powered H&E whole-slide image (WSI) analysis to predict recurrence in hormone receptor positive (HR+) early breast cancer (EBC).Org: Oncology Therapeutic Development, Lunit Inc.,
Abstract
BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).Org: National Cancer Center Hospital, Tokyo, Japan, Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China, Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Respiratory Medicine and Infectious Disease, Niigata University Medical & Dental Hospital, Niigata, Japan, Biological Therapy Oncology, Tianjin Cancer Hospital, Tianjin, China,
Abstract
Relationship between immune phenotype and treatment selection of Chemo-IO vs. IO-only in TPS-high NSCLC using hypothetical test-and-control group generation based on survival data extracted from phase III trials.Org: Oncology Therapeutic Development, Lunit Inc.,
Abstract
Deep learning–based chest CT model to predict treatment response to immune checkpoint inhibitors in non-small cell lung cancer independently and additively to histopathological biomarkers.Org: Oncology Therapeutic Development, Lunit Inc., Seoul National University Hospital, South Korea, Samsung Medical Center,
Abstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
Artificial intelligence (AI) analysis of tumor-infiltrating lymphocytes (TILs) in hematoxylin and eosin (H&E) slides to explore immune phenotypes in papillary thyroid cancer.Org: Lincoln Medical and Mental Health Center, Northwestern University Feinberg School of Medicine, Ascension Saint Francis Hospital, Lunit Inc., Oncology Therapeutic Development,
Abstract
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Kyung Hee University Hospital,
Abstract
Artificial intelligence (AI) –powered spatial analysis of tumor-infiltrating lymphocytes (TILs) for prediction of prognosis in resectable pancreatic adenocarcinoma (PDAC).Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center,
Abstract
PolyPEPI1018 vaccine in combination with TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC): A phase Ib study to evaluate safety, tolerability, immunogenicity and efficacy (OBERTO-201).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Mayo Clinic, Rochester, MN, Department of Laboratory Medicine and Pathology, University of Washington, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Effect of an artificial intelligence–powered programmed death-ligand 1 combined positive score analyzer in urothelial cancer on inter-observer and inter-site variability.Org: Oncology Therapeutic Development, Lunit Inc., Seoul National University Hospital, South Korea, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Correlation of fragmented pattern of tumor mass captured by artificial intelligence (AI)-powered whole-slide image (WSI) analysis with biased fibroblast expansion over tumor growth and distinct mutational signatures.Org: Oncology Therapeutic Development, Lunit Inc.,
Abstract
Deep learning-based ensemble model using hematoxylin and eosin (H&E) whole slide images (WSIs) for the prediction of MET mutations in non-small cell lung cancer (NSCLC).Org: Samsung Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Hematology-Oncology, Department of Medicine, Seoul Medical Center, Seo-Gu, South Korea, Sungkyunkwan University School of Medicine, Samsung Medical Hospital,
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,
Abstract
Real-world impact of olaparib use in patients (pts) with advanced pancreatic cancer (PC) harboring germline BRCA1/2 (gBRCA) mutations.Org: University of Verona, Oncology Section, Verona University Hospital Trust (AOUI Verona), IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia, University of Bologna,
Abstract
Artificial intelligence (AI) –powered H&E whole-slide image (WSI) analysis of tertiary lymphoid structure (TLS) correlates with immune phenotype and related molecular signatures in non–small-cell lung cancer.Org: Oncology Therapeutic Development, Lunit Inc., Northwestern University Feinberg School of Medicine,
Abstract
Home parenteral nutrition (HPN) using individually compounded PN administered via multi-chamber Eurotubes versus PN administered via 2/3-chamber bags in patients with metastatic or localized solid tumors requiring HPN: The randomized IKF-010 PEKANNUSS trial of AIO.Org: Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Center for Tumor Diseases (NCT),
Abstract
A PROSPECTIVE CLINICAL AND MRI STUDY OF IMMUNE CHECKPOINT INHIBITOR (ICI)-INDUCED MUSCULOSKELETAL MANIFESTATIONS MYO-FASCIITIS AND NOT SYNOVITIS IS THE PROMINENT IMAGING FINDINGOrg: Patras University Hospital, University of Patras Medical School, Rheumatology, Radiology and Nuclear Medicine Unit, Morgagni-Pierantoni Hospital, Forli, Italy, Oncology Therapeutic Development,
Abstract
ACQUIRED CELLULAR RESISTANCE TO THE DMARD SULFASALAZINE IS MEDIATED VIA UP-REGULATION OF A DRUG EFFLUX PUMP, THE ATP-BINDING CASSETTE (ABC) PROTEIN G2Org: Rheumatology, Pathology Deparment, Oncology Therapeutic Development, Vrije Universiteit Medical Centre, Amsterdam, Netherlands,
Abstract
B CELL DEPLETION WITH ANTI-CD22/CALICHEAMICIN IMMUNOCONJUGATE INHIBITS CLINICAL AND HISTOLOGICAL COLLAGEN-INDUCED ARTHRITISOrg: Inflammation Research, Pfizer Inc, St Louis, Wyeth Research, Cambridge University Hospitals NHS Foundation Trust, Chemical Sciences, Pearl River,